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Complement-mediated bactericidal activity has long been regarded as the serological correlate of protective
immunity against Neisseria meningitidis. This was affirmed in 2005 at a WHO-sponsored meningococcal
serology standardization workshop. The assay currently employed by most laboratories involves determining
surviving bacterial colony counts on agar as a readout which is labor-intensive, time-consuming, and not
amendable to rapid data analysis for clinical trials. Consequently, there is an acute need to develop a sensitive,
high-throughput bactericidal assay to enable a rapid and robust assessment of the effectiveness of vaccine
candidates. To this end, we have developed an automated, kinetic assay based on the fluorescent respiration
product of resazurin which reduces assay volume, shortens assay time, and facilitates automation of data
analysis. We demonstrate proof of concept for applicability of this high-throughput system with multiple
meningococcal strains and utilizing different lots of human complement. The assay is robust and highly
reproducible. Titers obtained by the fluorescence readout method are strongly correlated with the data
obtained using the conventional, agar plate-based assay. These results demonstrate that the detection of
bacteria that have survived the bactericidal reaction by measuring metabolic activity using a fluorescent dye
as an alternative readout is a promising approach for the development of a high-throughput bactericidal assay.
Goldschneider et al. documented that serum bactericidal
activity is inversely correlated with age-related incidence of
invasive meningococcal disease for serogroups A, B, and C and
demonstrated that the presence of bactericidal antibodies is
predictive of protection from the disease (7). Serum bacteri-
cidal titer was used as the primary endpoint measurement for
licensure of serogroup C polysaccharide conjugate vaccines (3)
and additionally for groups A, W135, and Y for licensure of
tetravalent polysaccharide conjugate vaccines (4). In clinical
trials for group B outer membrane vesicle vaccines, serum
bactericidal titers correlated with clinical efficacy and were
used as the primary measure of protection against disease in
several countries, including New Zealand, Norway, and Brazil
(9, 10, 12, 16). The importance of serum bactericidal activity as
a primary endpoint for evaluation of group B vaccines was
reaffirmed in a report issued by a WHO meeting on correlates
of protection and standardization for Neisseria meningitidis
group B in March of 2005 (2).
The assay format of the serum bactericidal assay (SBA) has
remained largely unchanged since Goldschneider et al. de-
scribed the in vitro test in 1969. In the conventional SBA, test
serum or plasma is serially diluted 2-fold usually from a start-
ing dilution of 1:2 or 1:4. Each dilution of the test sample is
then incubated with bacteria in the presence of an exogenous
source of active complement. Bactericidal antibodies in test
samples bind to the surface of the bacteria, resulting in the
activation of complement proteins and the formation of the
membrane attack complex, which results in bacteriolysis. Bac-
teria that survive complement-mediated lysis are enumerated
by plating on solid growth medium. Bactericidal antibody titers
are calculated as the reciprocal dilution of test sample that kills
50% or more of the bacteria inoculum in the assay. The enu-
meration of CFU in the conventional methodology restricts
several assay parameters of the SBA, including assay volume,
input number of bacteria, number of replicates tested, assay
duration, and the requirement of a human operator for colony
plating. The process is mostly performed manually, and inter-
operator variability has to be established as a source of error
when an assay is being qualified for clinical trials.
The burdens of the conventional assay are particularly ap-
parent during clinical trials when volumes of test samples are
limiting, particularly in infants, but test population and breadth
of bacterial strains to be tested are large. For meningococci,
the preferred SBA method involves use of human complement
obtained from normal volunteer donors. This is important be-
cause meningococci have known surface proteins that bind
complement components in a species-specific manner in order
to mask the bacteria and protect them from lysis (8). Many
normal human donors have intrinsic bactericidal activity
against meningococci; hence, a specific complement source
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must be obtained for each meningococcal isolate. Miniaturiz-
ing the test is important not only from the point of view of
economy of specimen but also for conservation of the valuable
resources of human donor complement.
In this study, we describe a modified version of the SBA that
is termed the high-throughput SBA (HT-SBA). It adheres to
the same assay principles as the conventional SBA but differs
in that the bactericidal reaction is not plated on agar but
instead receives a mixture of liquid growth medium and the
cell-permeable redox substrate resazurin dye (alamarBlue).
The assay is miniaturized to a 384-well format with reduced
volume and can be easily implemented with laboratory robotic
systems, thereby significantly increasing assay throughput. Res-
azurin is reduced to the fluorescent product resorufin in viable
cells. Both resazurin and resorufin are nontoxic to cells allow-
ing a homogenous assay format and kinetic measurement of
fluorescent signal over time. The signal is proportional to the
number of metabolically active cells and can be used to calcu-
late a bactericidal titer directly from the microplate using a
fluorescence plate reader. The HT-SBA differs from previous
attempts to develop an alternative non-agar-based readout for
the bactericidal reaction (13–15) in that it utilizes a kinetic
measurement to optimize the time point selected for titer
determination for each assay run. Our kinetic approach allows
for the optimization of the signal differential between wells
with high versus low bacterial counts following the bactericidal
reaction such that the most sensitive measurements are
achieved. Any changes in assay parameter values such as dif-
ferent growth characteristics of various bacterial strains are
captured in the kinetic growth data, allowing for better accu-
racy in titer calculations. We demonstrate a strong correlation
of titers between the conventional and HT-SBA using different
MenB strains, lots of human complement, and test samples.
MATERIALS AND METHODS
Strains and reagents. Meningococcal group B clinical isolates NZ98-254,
H44/76, and 5/99, with serotype and antigenic compositions previously described
(5), were stored frozen as stock cultures at 80°C in 10% skim milk (232100;
Becton Dickinson). Strains were thawed and grown overnight on chocolate agar
at 37°C in 5% CO2 for use the following day in the bactericidal assay.
Serum/plasma samples. The serum samples used for this study were from two
randomized, single-blind phase I studies conducted to assess the safety, tolera-
bility, and immunogenicity of a meningococcal serogroup B recombinant vaccine
administered alone or in combination with outer membrane vesicles from the
Norwegian serogroup B strain H44/76 (17). The serum panel was selected to
give a broad range of bactericidal titers. Authors were blinded as to which
vaccine group the individual samples were derived. When plasma was used as the
source of human complement, heparin (H3149; Sigma) was added to both the
conventional and the high-throughput assays at a 1.0-U/ml final concentration.
Conventional SBA. The standardized serum bactericidal assay (SBA) was
performed using human complement as described previously (1). Frozen stock
meningococcal strains were thawed and grown overnight on chocolate agar at
37°C in 5% CO2 for use in the bactericidal assay. The following day, isolated
colonies were pooled and then subcultured in Mueller-Hinton broth (MHB)
(275730; Becton Dickinson) for approximately 2 h to the mid-log phase of
growth. Bacteria were then diluted in assay diluent, consisting of Dulbecco’s
phosphate-buffered saline (DPBS) (21-030-CV; Mediatech) with 1% bovine se-
rum albumin (BSA) (A7888; Sigma) supplemented with 0.1% glucose (G5767;
Sigma) to a concentration of approximately 2.0  104 bacteria/ml for use in the
assay. Test sera were serially diluted 2-fold in assay diluent in 96-well plates
starting from a 1:2 dilution and then incubated for 60 min with bacteria and 25%
human serum complement lacking intrinsic bactericidal activity in a total reac-
tion volume of 80 l. Aliquots were spread onto chocolate agar plates and grown
overnight. Colonies were counted after 16 to 20 h of growth, and the 50% titer
of each test specimen was determined relative to the time zero (t0) inoculum.
Bacterial cultures were grown in a humidified incubator at 37°C in 5% CO2 at
each step.
HT-SBA. The high-throughput serum bactericidal assay (HT-SBA) adheres to
the same assay principles as the conventional SBA but diverged from the stan-
dard assay as follows. The bactericidal reaction was performed in a 384-well
microtiter black flat-bottom plate (781209; Greiner) in 20 l of a reaction
volume. Unless otherwise stated, all experiments used a 5-l starting inoculum of
1.5  105 CFU/ml. Following completion of the bactericidal reaction, each well
received 20 l of a mixture of liquid growth medium consisting of MHB or
DPBS, supplemented with glucose and alamarBlue (DAL1100; Invitrogen); the
plate was sealed with a gas-permeable optically clear film (2978-2100; USA
Scientific) and incubated at 37°C in 5% CO2 in 98% humidity. alamarBlue was
prepared fresh the day of use. A serum normalization control series that lacks
bactericidal activity against the strain of interest was included in each experiment
to monitor the effect of serum quenching of resorufin. At hourly intervals, the
plate was removed from the incubator and read to detect the fluorescence signal
generated when resazurin is reduced to resorufin by bacterial respiration using a
fully automated robotic platform built by GNF Systems (11). The data were
collected for 16 h and then analyzed for titer determination in a three-step
process. First, the bacterial growth curve derived from changes in fluorescence
was plotted using controls that monitor growth in human plasma or serum
complement lacking bactericidal activity. Second, a time point used for titer
determination where the bacteria were in the exponential growth phase and the
signal was at least 50% of the plateau was selected. Third, after the time point
was selected, the data were normalized to the above-mentioned serum normal-
ization control series and analyzed by a four-parameter logistic curve fitting as
described in detail in Results. The reciprocal serum dilution that resulted in a
50% reduction of fluorescence (IC50) relative to the normalized maximum signal
was reported as the titer of the sample.
RESULTS
Determination and optimization of assay parameter values.
(i) Identification of grow-out media. Successful miniaturization
of the SBA was dependent upon the identification of a readout
method that will allow the quantification directly in the well of
bacteria that survive challenge with antibody and active com-
plement. This can be accomplished only with suitable grow-out
media that allow surviving bacteria to recover and proliferate.
In Fig. 1A, growth curves are shown from 7 successive runs for
the group B strain, NZ 98/254, using Mueller-Hinton broth
(MHB) supplemented with 0.25% glucose and alamarBlue as
the grow-out medium. The curves are plotted following treat-
ment for 1 h with serum complement which has no intrinsic
bactericidal activity. This postreaction growth phase is analo-
gous to plating a sample on chocolate agar, which also allows
growth of surviving bacteria that will go on to form colonies.
The growth curves of NZ 98/254 following incubation with
complement are highly reproducible, with the exponential
phase of growth typically between the 4th and 9th hours fol-
lowing addition of the grow-out medium. As the scope of the
study was expanded to include different bacterial strains, com-
plement sources, and test sera, it was determined that MHB
supplemented with 0.25% glucose was not universally applica-
ble for use as a grow-out medium. In order to circumvent this
problem, growth in alternative medium was examined. DPBS
supplemented with 0.1% glucose was subsequently found to
support NZ98/254 growth similar to MHB (Fig. 1B) and have
the best compatibility profile for all strains tested.
(ii) Time point selection for titer determination. In each of
the seven individual experiments represented in Fig. 1, eight
human serum samples were tested in parallel by both the
conventional and the HT-SBA methods and the resulting titers
were compared. In the HT-SBA, titers were calculated for all
eight samples at each time point from 4 to 9 h after the
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addition of alamarBlue. These results are plotted for each time
point in Fig. 2. As demonstrated by the linear regression of
titers (Table 1), in this series of assays the HT-SBA data
obtained at the 5-, 6-, and 7-h time points showed the best
agreement with the titers obtained in the conventional SBA. In
order to automate time point selection and reduce operator
bias, a performance-based selection process was assessed. In
this case, the time point just before the fluorescence signal
reached 90% of the signal plateau (AFU90) was used. The
AFU90 can differ from experiment to experiment, as observed
in the seven runs shown in Fig. 1, presumably due to slight
variation in bacterial inoculum at the start of each assay. In this
set of runs, the actual time points corresponding to the AFU90
ranged between 7 and 8 h. When the AFU90 was used as the
selection criterion, the linear regression of titers remained high
(R2  0.907).
(iii) Serum normalization. In the SBA, test samples were
serially diluted and then combined with exogenous comple-
ment and bacteria. Consequently, each individual sample in a
dilution series has a different final concentration of serum. It is
a documented feature of alamarBlue that the fluorescence
signal can be quenched by the presence of serum (6). This
quenching phenomenon was also observed in the HT-SBA and
can result in an overestimation of titer. In order to correct for
this effect, we introduced an experimental control, the serum
normalization series. This series involves the use of a negative-
control serum, which lacks intrinsic bactericidal activity, seri-
ally diluted in the same manner as the test sera. This control
series lacks bactericidal activity; hence, any loss in the fluores-
cence signal, as the serum concentration increases, is due to
serum absorption of resorufin (Fig. 3A, closed squares). In
order to normalize data obtained for each serum dilution se-
ries, the median fluorescence intensity of the triplicate values
of the serum normalization control is computed for each com-
bination of time point and dilution point. Each test serum
value is then divided by the normalization factor for its corre-
sponding time and dilution. In the example shown in Fig. 3A,
test sample 2 had a titer of 2 by the conventional SBA
method; however, in the HT-SBA the titer for sample 2 would
have been 9.6 without normalization (closed diamonds). After
normalization using corresponding dilution points from the
normalization control serum, when recalculated the titer was
determined to be 2, in agreement with the titer obtained
from the conventional SBA (Fig. 3B).
(iv) Curve fitting. After the appropriate time point was cho-
sen from the postreaction grow-out phase of the assay for
interpretation of data and the raw values were normalized to
correct for the serum quenching effect, the antibody titer for
each test sample was determined as the IC50 value of the
reciprocal of the dilution by fitting sample fluorescence data
with a 4-parameter logistic equation. The curve-fitting con-
straints of the normalized data were set to have an upper limit
bound between 0.8 and 1.5, a lower limit between 0 and 0.15,
and a Hill slope between3.0 and3.0. One outlier is allowed
for each curve fitted. The equation used for this analysis is as
follows: response  bottom  {[top  bottom]/[1  (concen-
tration/IC50)
Hill]}.
Comparison of assays. The relative performance of the HT-
SBA was assessed, including assay reproducibility, robustness,
and linearity, to determine the comparability of results in par-
allel with the conventional SBA. For the conventional SBA,
each sample run was assayed once in a 96-well microtiter plate
per test and the bactericidal reaction was plated on agar in
duplicate for titer determination. The HT-SBA was carried out
FIG. 1. (A) Growth curve of NZ98-254 in MHB-0.25% glucose measured by fluorescence signal generated when resazurin is reduced into
resorufin by bacterial respiration. (B) Comparable growth is observed when NZ98-254 was grown in MHB-0.25% glucose or DPBS-0.1% glucose,
both containing 25% human serum. Data points represent the averages and standard deviations for six separate fluorescence measurements.
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FIG. 2. Correlation of serum titers from nonimmunized human adults (samples 1 and 2) and immunized human adults (samples 3, 4, 5, 6, 7,
and 8) determined by the HT-SBA compared to those determined by the conventional assay at six different time points.
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in higher-density 384-microtiter-plate format, with the reaction
volume reduced by 75%. Test serum was assayed in triplicate,
and the fluorescence signal for each replicate was analyzed to
determine the corresponding reciprocal serum dilution to the
IC50 of the normalized fluorescence signal. A sample with a
negative titer of 2 was assigned a value “1” for statistical
analysis purposes. For all data discussed below, the time point
just before the growth curve reached 90% of the plateau value
point (AFU90) was used for titer calculation, unless otherwise
stated. For the purpose of comparing the two methods, titer
values obtained by the HT-SBA and the standardized SBA
were both log transformed.
(i) Reproducibility. To demonstrate that the HT-SBA is
robust and can generate reproducible data, a panel of 8 human
sera covering a range of titers were assayed seven times in
parallel with the conventional SBA using strain NZ98/254, as
shown in Fig. 2. Good agreement was seen between the two
assays, with a Pearson product-moment correlation coefficient
(R2) of 0.935 when the AFU90 was used as the basis for time
point selection.
(ii) Robustness with different inoculum concentrations.
Given that the survival of bacteria after the bactericidal assay
is assayed by fluorescence signal rather than enumeration of
CFU on an agar plate, it is important to know the limitation
and robustness of the HT-SBA when variable bacterial inocu-
lum is used in each assay. To assess this, a panel of five test sera
were tested against strain NZ98/254 with inoculum concentra-
tions 10-fold higher and lower than the 105 CFU/ml typically
used in the HT-SBA. In examining the growth curves, different
inoculum concentrations generated fluorescence signals at dif-
ferent rates and reached the plateau at different time points
(Fig. 4). Given the difference in growth kinetic, the data set
from each inoculum was calculated based on the AFU90 from
each run. The data from these runs are summarized in Fig. 5
and Table 2, which demonstrates that varying the concentra-
tion of bacterial inoculum added to each well in the HT-SBA
from 104 to 106 per ml had little effect on the correlation of
bactericidal titers compared to the conventional SBA, where
the inoculum added is approximately 104.
(iii) Linearity. In order to assess linearity of the HT-SBA, a
series of samples were made from a high-titer serum which was
diluted by factors of 4, 16, 32 and 64 and then tested in con-
current assays with the conventional or HT-SBA using strain
NZ98/254. Samples were diluted in assay diluent consisting of
DPBS and 1% bovine serum albumin. As shown in Fig. 6, using
simple linear regression we observed linearity between the
titers obtained and the predilution factor in both assay meth-
ods, with a slope of 1.18 and R2 values of 0.988 for the HT-SBA
and a slope of 1.05 and an r2 of 0.995 for the conventional SBA.
FIG. 3. Panel A shows the fluorescence signal generated by test serum (closed diamonds) and the normalization control (closed squares). Panel
B demonstrates that after normalization, the test serum has little bactericidal activity, and the titer is determined to be 2. The dashed line
represents approximately 50% killing signal.
TABLE 1. Linear regression values for data shown in Fig. 2
Time point
ya
a b R2
4 0.039 0.133 0.045
5 0.117 1.024 0.932
6 0.160 0.992 0.950
7 0.198 0.909 0.934
8 0.240 0.813 0.927
9 0.103 0.793 0.945
AFU90
b 0.187 0.907 0.935
a y  a  b  x, where a is the y intercept and b is the slope.
b The time point at which the fluorescence signal reaches 90% of the signal
plateau (AFU90) ranged between 7 and 8 h. FIG. 4. Growth curves of NZ98/254 at different starting inoculum
concentrations. Shown are average fluorescence signals and standard
deviations for 6 wells.
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(iv) Additional meningococcal strains. Strain H44/76 was
tested concurrently in the conventional and HT-SBA in two
independent experiments. Serum samples with low titers (64)
were assayed (Fig. 7), and good agreement in titers was ob-
served between the conventional and the HT-SBA methods
(R2  0.8659). No false positives for the HT-SBA were de-
tected. In a similar comparison using strain 5/99 and a sample
set with a broader range of titers, between 2 and 1,024 (Fig.
8), good agreement in titers was also observed between the two
methods at 7 h (R2  0.98) and at 8 h (R2  0.9865) of
bacterial growth after the bactericidal reaction in the HT-SBA.
(v) Use of plasma complement. With the use of plasma as
the source of exogenous complement in combination with low
serum dilutions, clotting in assay wells has been observed in the
conventional assay in some instances. This can be controlled
with the addition of anticlotting agents, such as heparin, which
was used in both the standard assay and the HT-SBA. Given
the format changes in the HT-SBA, a subset of serum samples
was tested using aphaeresis plasma as the complement source
to determine the compatibly of plasma with the HT-SBA.
Samples were assayed in both the conventional assay and the
HT-SBA with either serum or plasma complement and the
resulting titers compared. Results were consistent across both
assay methods, largely independent of the complement source
used. The only notable difference was associated with plasma
complement B, which in both assays displayed titers slightly
lower than those obtained with serum complement (Fig. 9).
DISCUSSION
One of the most critical stages in vaccine development is the
testing of vaccine effectiveness in the target population. A
clinical trial often involves thousands of subjects and multiple
samples collected from each individual during various stages of
the trial. It is important to have an efficient method for assay-
ing the samples and determining the effectiveness of the vac-
cine. The SBA is the gold standard assay for the assessment of
meningococcal vaccines. The manual format in the conven-
tional assay poses significant demands on critical reagents due
to high volume requirements, which places constraints on the
number of assays that can be performed on any given specimen
and limits the throughput of the assay.
The high-throughput bactericidal assay adheres to the same
assay principle as the standard SBA. Meningococcal bacteria
were incubated with immune serum and human complement,
FIG. 6. Demonstration of the linearity of the alamarBlue assay by
serial dilution of the test sample. A test sample is prediluted at differ-
ent ratios (x axis) and assayed in parallel for CFU or alamarBlue
readouts. In both cases, the titer calculated is log transformed and
plotted on the y axis. Simple linear regression between titer deter-
mined and dilution factor were determined, and the slope and corre-
lation coefficients are listed in the legend.
FIG. 7. Comparison of titers from the conventional assay and the
HT-SBA using a panel of low-titer serum samples from nonimmunized
human adult donors against the 44/76-SL strain.
FIG. 5. Comparison of titers from serum samples (n  5) obtained
by the conventional assay and the alamarBlue assay over a range of
starting inoculum concentrations.
TABLE 2. Linear regression values shown in Fig. 5
No. of cells/ml
(time point) Slope
y intercept when
x  0.0 r
2
10,000 (10 h) 0.9107  0.03386 0.07361  0.05833 0.985
50,000 (10 h) 0.9040  0.04631 0.1041  0.07977 0.972
100,000 (8 h) 0.8862  0.03774 0.08079  0.06501 0.980
500,000 (7 h) 0.8984  0.03348 0.06638  0.05767 0.985
1,000,000 (6 h) 0.8893 0.05166 0.08170  0.08897 0.964
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and the percentage of bacteria that survive was determined.
The procedure diverges from that of the conventional SBA in
that the surviving bacteria in each well were provided with a
mixture of liquid growth medium and respiration dye resaz-
urin, which is used to monitor bacterial growth following the
reaction, instead of plating the bactericidal reaction on a solid
growth medium to allow surviving bacteria to form colonies.
The bacteria reduce the dye to resorufin by respiration, which
generates a fluorescence signal that accumulates over time.
The data were collected kinetically and analyzed to determine
a titer based on survival curves generated by the 2-fold serial
dilution of sera from immunized subjects. The growth curve of
bacteria in normal human serum lacking intrinsic bactericidal
activity is plotted from data collected each hour for 16 h. A
time point wherein the increase in fluorescence signal is linear
with respect to time and the signal is at least 50% of the
plateau is selected for test sample titer determinations. Once
the time point is chosen, all data were normalized to correct
for nonspecific fluorescence quenching by serum. For each test
sample, the curve is then fitted by the four-parameter logistic
model and the bactericidal titer is calculated as the reciprocal
dilution of the half-maximal peak of growth.
The HT-SBA differs from previous attempts to develop flu-
orescent or colorimetry-based readouts for the bactericidal
reaction (13–15) in that it utilizes a kinetic measurement to
optimize the time point selected for titer determinations. This
is one of the key features of the HT-SBA. This kinetic ap-
proach is utilized to ensure the most robust correlation be-
tween the fluorescence signal and the number of surviving
bacteria present in the test well. For this reason, care was taken
that the surviving bacteria in the wells were in the log phase of
growth while the alamarBlue was present, thereby optimizing
the signal differential between wells with high bacterial counts
from wells where few bacteria survived the bactericidal reac-
tion. From these studies, we have concluded that the optimal
time frame for titer calculation by fluorescence data analysis
corresponds to those time points where the accumulation of
fluorescence signal is at its steepest and the fluorescent signal
FIG. 8. Comparison of titers from nonimmunized human adults (samples 28, 31, 33, 35, 37, and 40) and immunized human adults (samples 29,
30, 32, 34, 36, 38, 39, and 41) obtained for strain 5/99 in the conventional assay and the HT-SBA after 7 or 8 h of growth following the bactericidal
reaction.
FIG. 9. Comparison of different human complement sources on titers from both the conventional assay and the HT-SBA.
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is at least 50% of the signal plateau. This kinetic approach
allows the assay to be easily adapted to changes in assay pa-
rameter values resulting from different growth characteristics
of various bacterial strains and sources of reagents (e.g., dif-
ferent complement sources).
A second important feature which is needed for accurate
data acquisition is the inclusion of the serum normalization
control. In the HT-SBA, the overall concentration of test se-
rum or plasma can range from 75% to 25% of the reaction
volume, depending on the starting dilution of the test sample
in combination with the complement used in the test. The
fluorescence signal of alamarBlue can be quenched at high
serum concentrations; therefore, correcting for the effect can
greatly reduce the occurrence of false positives in the assay.
A third feature of importance to the HT-SBA is the use of
an appropriate growth medium to promote robust recovery of
bacteria that have survived the bactericidal reaction which, in
our experience, needs to be empirically determined. In pilot
studies, Muller-Hinton broth was a reasonable choice for this
purpose, as it performed well and was used to prepare bacteria
for inclusion in the bactericidal reaction itself. As the strain
panel was extended, we found that the growth of bacteria for
some strains was suboptimal, which might have resulted from
unexpected incompatibility between components in the post-
reaction grow-out phase of the HT-SBA. Several different
types of media were examined, including yeast extract and
medium supplemented with Isovitalex, all with various results
(data not shown). We found that DPBS supplemented with
glucose appeared to be a generally compatible medium; how-
ever, there is no guarantee that this will be true for any new
strain tested.
An important difference between the conventional SBA and
the HT-SBA is the baseline that is used to define the bacteri-
cidal effect of antibodies and complement. Many laboratories
that perform the conventional SBA, including our own, use the
number of input CFU, also termed the t0 bacterial count, as the
basis for determining the 50% kill endpoint. Thus, the number
of surviving bacteria must be less than half the number of input
bacteria for a sample to be scored as having a positive titer. A
widely used alternative to this approach employs CFU enu-
merated at t60 to determine the 50% kill endpoint of a test
sample. With this approach, titer determination is based not on
the number of input bacteria but rather on the number that
have survived during the 60-min incubation time comparable
to all sample tests. It should be noted that titer determination
in the HT-SBA is based on the fluorescent signal associated
with the serial dilution of each sample. It is not possible to get
a t0-equivalent fluorescence reading in the HT-SBA, because
the combination of bacterial inoculum and respiration rate will
not produce sufficient fluorescent product (resorufin) within
the first few measurements. Only after 3 to 4 h of bacterial
growth is the fluorescent signal generated by resorufin detect-
ible above the background. In the HT-SBA, all bacteria were
plated simultaneously and the fluorescence signals from the
surviving bacteria incubated with test sera were compared with
the fluorescence signal from a negative-control sample incu-
bated with bacteria and complement but without antibody.
Thus, the 50% threshold used for titer determination in the
HT-SBA represents inhibition of bacterial growth in compar-
ison to the appropriate growth and negative controls rather
than a reduction below half of the input CFU level. For the
strains that were evaluated in this study, very good agreement
was seen between the endpoint titer results from the conven-
tional assay using t0 for titer calculations and the growth ki-
netics methodology used in the HT-SBA.
The goal of developing the HT-SBA was to improve the
assay throughput while maintaining good agreement with
the titers obtained using the conventional bactericidal assay.
In this report, we described the development of a high-
throughput assay and proof-of-principle studies which detail
the reproducibility, linearity, robustness, and applicability of
the assay with various meningococcal strains and comple-
ment sources. Even when the test conditions were varied,
the HT-SBA result maintained a strong correlation with the
result obtained with the standardized agar-based assay. The
HT-SBA has two significant improvements upon previous
work in the development of alternative readouts of SBA
(13–15): (i) the collection of kinetic fluorescence readings
during the bacteria recovery phase allows us to identify the
best time point for titer determination, optimizing assay
sensitivity, and (ii) the introduction of a serum normaliza-
tion control is used to correct for signal quenching, which
improves the accuracy of titer determination.
The advantages of the HT-SBA format for clinical studies
are numerous: (i) the process can now be fully automated,
thereby limiting operator’s exposure to biohazardous materi-
als; (ii) it will be easier to standardize across different labora-
tories and operators; (iii) lower sample volume usage, which is
particularly useful for the measurement of vaccine effective-
ness in infant populations; (iv) reagent costs and manual assay
time will be significantly reduced; and (v) the higher-density
format also allows each test sample to be tested in a wider
dilution range, reducing the need for repeat testing. In each
case, the HT-SBA is a clear improvement over the conven-
tional, agar-based bactericidal assay, which enables the HT-
SBA to be applied in large-scale studies with greater efficiency
without compromising data quality.
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